Inhibiting Monoacylglycerol Acyltransferase 1 Ameliorates Hepatic Metabolic Abnormalities but Not Inflammation and Injury in Mice*

Background: Mogat1 inhibition improves glucose metabolism in obese mice, but its effects on liver injury are unknown. Results: Mogat1 knockdown improved hepatic metabolic abnormalities but did not reduce liver inflammation or injury. Conclusion: Hepatic injury and metabolic abnormalities are separable disease entities. Significance: Attention to liver injury markers should be made when evaluating metabolic therapies. Abnormalities in hepatic lipid metabolism and insulin action are believed to play a critical role in the etiology of nonalcoholic steatohepatitis. Monoacylglycerol acyltransferase (MGAT) enzymes convert monoacylglycerol to diacylglycerol, which is the penultimate step in one pathway for triacylglycerol synthesis. Hepatic expression of Mogat1, which encodes an MGAT enzyme, is increased in the livers of mice with hepatic steatosis, and knocking down Mogat1 improves glucose metabolism and hepatic insulin signaling, but whether increased MGAT activity plays a role in the etiology of nonalcoholic steatohepatitis is unclear. To examine this issue, mice were placed on a diet containing high levels of trans fatty acids, fructose, and cholesterol (HTF-C diet) or a low fat control diet for 4 weeks. Mice were injected with antisense oligonucleotides (ASOs) to knockdown Mogat1 or a scrambled ASO control for 12 weeks while remaining on diet. The HTF-C diet caused glucose intolerance, hepatic steatosis, and induced hepatic gene expression markers of inflammation, macrophage infiltration, and stellate cell activation. Mogat1 ASO treatment, which suppressed Mogat1 expression in liver and adipose tissue, attenuated weight gain, improved glucose tolerance, improved hepatic insulin signaling, and decreased hepatic triacylglycerol content compared with control ASO-treated mice on HTF-C chow. However, Mogat1 ASO treatment did not reduce hepatic diacylglycerol, cholesterol, or free fatty acid content; improve histologic measures of liver injury; or reduce expression of markers of stellate cell activation, liver inflammation, and injury. In conclusion, inhibition of hepatic Mogat1 in HTF-C diet-fed mice improves hepatic metabolic abnormalities without attenuating liver inflammation and injury.

[1]  D. Rader,et al.  Lipidomic Analyses of Female Mice Lacking Hepatic Lipase and Endothelial Lipase Indicate Selective Modulation of Plasma Lipid Species , 2014, Lipids.

[2]  M. Graham,et al.  Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice , 2014, Diabetes.

[3]  H. Cao,et al.  Role of diet and nutritional management in non‐alcoholic fatty liver disease , 2013, Journal of gastroenterology and hepatology.

[4]  Soumitra S Ghosh,et al.  Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[5]  Toshihide Kobayashi,et al.  A high‐fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non‐alcoholic steatohepatitis in mice , 2013, Clinical and experimental pharmacology & physiology.

[6]  J. McManaman,et al.  Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease[S] , 2013, Journal of Lipid Research.

[7]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[8]  D. Ford,et al.  Cholesterol efflux analyses using stable isotopes and mass spectrometry. , 2013, Analytical biochemistry.

[9]  S. Kaneko,et al.  Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis , 2012, PloS one.

[10]  J. Seong,et al.  Nuclear receptor PPARγ-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis , 2012, Proceedings of the National Academy of Sciences.

[11]  P. Li,et al.  Cidea promotes hepatic steatosis by sensing dietary fatty acids , 2012, Hepatology.

[12]  S. Klein,et al.  Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver[S] , 2012, Journal of Lipid Research.

[13]  B. Neuschwander‐Tetri,et al.  Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[14]  R. Juyal,et al.  Genetically modified mouse models for the study of nonalcoholic fatty liver disease. , 2012, World journal of gastroenterology.

[15]  John A. Bowden,et al.  Analysis of cholesteryl esters and diacylglycerols using lithiated adducts and electrospray ionization-tandem mass spectrometry. , 2011, Analytical biochemistry.

[16]  S. Imai,et al.  Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. , 2011, Cell metabolism.

[17]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[18]  J. Shaw,et al.  Validation of the non‐alcoholic fatty liver disease activity score , 2011, Alimentary pharmacology & therapeutics.

[19]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[20]  Y. Qian,et al.  The Acyl CoenzymeA:Monoacylglycerol Acyltransferase 3 (MGAT3) Gene is a Pseudogene in Mice but Encodes a Functional Enzyme in Rats , 2011, Lipids.

[21]  S. Woods,et al.  High‐fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis , 2010, Hepatology.

[22]  B. Finck,et al.  Peroxisome Proliferator-activated Receptor-γ Coactivator-1α (PGC-1α) Stimulates VLDL Assembly through Activation of Cell Death-inducing DFFA-like Effector B (CideB)* , 2010, The Journal of Biological Chemistry.

[23]  T. Hanafusa,et al.  Development of Fibrosis in Nonalcoholic Steatosis through Combination of a Synthetic Diet Rich in Disaccharide and Low-Dose Lipopolysaccharides in the Livers of Zucker (fa/fa) Rats , 2009, Journal of clinical biochemistry and nutrition.

[24]  Yuguang Shi,et al.  Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.

[25]  A. K. Agarwal,et al.  Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. , 2009, Cell metabolism.

[26]  A. Sanyal,et al.  Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. , 2008, Seminars in liver disease.

[27]  T. Harris,et al.  Alterations in Hepatic Metabolism in fld Mice Reveal a Role for Lipin 1 in Regulating VLDL-Triacylglyceride Secretion , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[28]  N. Anderson,et al.  Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis , 2008, Pharmacological Reviews.

[29]  M. Honda,et al.  Lipid‐induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet , 2007, Hepatology.

[30]  Jing Ye,et al.  Cideb Regulates Diet-Induced Obesity, Liver Steatosis, and Insulin Sensitivity by Controlling Lipogenesis and Fatty Acid Oxidation , 2007, Diabetes.

[31]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[32]  Yuguang Shi,et al.  Catalytic properties of MGAT3, a putative triacylgycerol synthases⃞ Published, JLR Papers in Press, December 14, 2006. , 2007, Journal of Lipid Research.

[33]  R. E. Pitas,et al.  Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1 s⃞ Published, JLR Papers in Press, July 8, 2006. , 2006, Journal of Lipid Research.

[34]  G. Svegliati-Baroni,et al.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. , 2006, The American journal of pathology.

[35]  S. Burgess,et al.  Diminished Hepatic Gluconeogenesis via Defects in Tricarboxylic Acid Cycle Flux in Peroxisome Proliferator-activated Receptor γ Coactivator-1α (PGC-1α)-deficient Mice* , 2006, Journal of Biological Chemistry.

[36]  A. Suzuki,et al.  Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[37]  B. Chang,et al.  Protection against Fatty Liver but Normal Adipogenesis in Mice Lacking Adipose Differentiation-Related Protein , 2006, Molecular and Cellular Biology.

[38]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[39]  L. E. Hammond,et al.  Mitochondrial Glycerol-3-Phosphate Acyltransferase-Deficient Mice Have Reduced Weight and Liver Triacylglycerol Content and Altered Glycerolipid Fatty Acid Composition , 2002, Molecular and Cellular Biology.

[40]  G. Schonfeld,et al.  Hepatic Fatty Acid Synthesis Is Suppressed in Mice With Fatty Livers Due to Targeted Apolipoprotein B38.9 Mutation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[41]  M. Clemens,et al.  Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Coleman,et al.  Hepatic monoacylglycerol acyltransferase is regulated by sn-1,2-diacylglycerol and by specific lipids in Triton X-100/phospholipid-mixed micelles. , 1994, The Journal of biological chemistry.

[43]  R. Coleman,et al.  Selective retention of essential fatty acids: the role of hepatic monoacylglycerol acyltransferase. , 1993, The American journal of physiology.

[44]  R. Green,et al.  The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. , 2004, Journal of hepatology.

[45]  D. Volsky,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinformatics.